It can be hypothesized that compounds that inhibit STAT3 activation could be effective in reducing the oncogenic potential of this protein, and provide targeted therapy for hypoxic, chemotherapy-resistant ovarian cancer. This evidence concerns the gene STAT3 and ovarian cancer.